Kayne Anderson Rudnick Investment Management
BCYC

Kayne Anderson Rudnick Investment Management’s Bicycle Therapeutics BCYC Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30
Closed -$1K – 610
2022
Q1 		$1K Buy
+30
New +$1.4K ﹤0.01% 618

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's BCYC Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Bicycle Therapeutics (BCYC) in Q2 2022, closing a stake of 30 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in BCYC in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 81 funds tracked by Wall St. Rank hold BCYC as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Bicycle Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 30 Bicycle Therapeutics shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Bicycle Therapeutics in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Bicycle Therapeutics position peaked at $1K in Q1 2022.
  • 81 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.